Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Currently Reading
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019

Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the need for standardizing the use of real-world evidence for measuring endpoints in clinical practice.


Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the need for standardizing the use of real-world evidence for measuring endpoints in clinical practice.

Transcript

How do challenges associated with variation in the use of real-world evidence for measuring endpoints in clinical practice highlight the need for standardization, and are there any potential ways that have been identified to do this?  

 I think harmonization of results from different groups is absolutely necessary. Friends of Cancer Research actually has provided some leadership. They recently did a study looking at the management of lung cancer using multiple groups. They are now doing a second iteration of that, and we’re happy to say that we’re going to be participating and this will be an opportunity to use common terms and see how much overlap of agreement there is from different data sources. 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up